checkAd
    Startseite > Aktien > Allakos > Nachrichten
    Allakos Aktie
    1,4500
     
    USD
    +22,36 %
    +0,2650 USD
    Letzter Kurs 02:00:00 Nasdaq
    1,4500
     
    USD
    1.500 STK
    Geldkurs 16.05.24
    1,4600
     
    USD
    11.200 STK
    Briefkurs 16.05.24
    ISIN: US01671P1003 · WKN: A2JQTK · SYM: ALLK · USA

    Neueste Nachrichten

    Allakos Provides Business Update and Reports First Quarter 2024 Financial Results
    09.05.24 · globenewswire · Allakos
    Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results
    14.03.24 · globenewswire · Allakos
    Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
    26.02.24 · globenewswire · Allakos
    Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
    12.02.24 · globenewswire · Allakos
    Allakos Announces a Restructuring to Focus on Development of AK006
    16.01.24 · globenewswire · Allakos
    Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints
    16.01.24 · globenewswire · Allakos
    Allakos Provides Business Update and Reports Third Quarter 2023 Financial Results
    13.11.23 · globenewswire · Allakos
    Allakos Appoints Neil Graham to its Board of Directors
    30.08.23 · globenewswire · Allakos
    Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors
    02.08.23 · globenewswire · Allakos
    Allakos Presents Preclinical Data at EAACI Hybrid Congress 2023 Highlighting Lirentelimab and AK006 Mechanisms of Mast Cell Inhibition
    12.06.23 · globenewswire · Allakos
    Allakos Announces Upcoming Presentation on Lirentelimab and AK006 Mast Cell Inhibition at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2023
    05.06.23 · globenewswire · Allakos